Withdrawn trial sought to boost Cancer-Killing power before surgery
NCT ID NCT06829199
Summary
This study aimed to see if adding an experimental drug called boserolimab to standard pre-surgery treatment could better treat high-risk, early-stage triple-negative breast cancer. It planned to test the safety of this combination and measure how many patients had no detectable cancer left after treatment. The study was designed for patients newly diagnosed with this aggressive cancer type, but the trial was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cheng Kung University Hospital ( Site 0901)
Tainan, 704, Taiwan
-
Optum Care Cancer Center ( Site 0004)
Las Vegas, Nevada, 89102, United States
Conditions
Explore the condition pages connected to this study.